GBP2 and Parkinson disease: We found that GBP2 was significantly upregulated in the substantia nigra of PD patients, and in both MPTP-induced and A53T transgenic mouse models, as well as in MPP<sup>+</sup>-treated or A53T α-synuclein-overexpressing SH-SY5Y cells.